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Abstract. ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including
real-world evidence, in the decision-making process for new treatments in Alzheimer’s disease, and to advance key concepts
in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to
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make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed
conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term
benefit.
Keywords: Alzheimer’s disease, data sharing, data systems, health policy, patient outcome assessment, real-world clinical
trials, systems integration
INTRODUCTION
In Alzheimer’s disease (AD), monitoring of patient
outcomes is key to mapping disease progression,
establishing the effectiveness and safety of interven-
tions, and optimizing disease management. However,
this is challenging in a real-world context as, unlike
in clinical trials, data on clinical and patient-reported
outcomes are not consistently collected in routine
clinical practice post diagnosis, and there is little
consensus on which outcomes to collect [1]. As AD
onset may precede symptoms by many years [2,
3], measures informing early detection and disease
progression are also required to develop treatments
targeting preclinical disease.
Using real-world evidence (RWE) to demonstrate
the value of early interventions is becoming increas-
ingly important, as a treatment benefit may not be
realized until later in the disease course and may be
difficult to capture in trials shorter than 5 years [4,
5]. Synthesis of data, including broad-based national
population electronic health records (EHRs) and in-
depth research data from population and clinical
cohorts, and modeling of the effect of early treat-
ment on long-term clinical outcomes in real-world
datasets, can provide effectiveness and cost evi-
dence to help decision-makers assess the value of
new disease-modifying treatments. This evidence and
other evidence from real-world data can also be
used to inform other aspects of AD research and
clinical practice, such as public health (e.g., pri-
mary and secondary prevention) and the evaluation
of non-pharmacological interventions. Nevertheless,
the utility of RWE approaches varies considerably,
with most studies being underpowered due to limited
data access, sample size and length and frequency
of follow-up. Also, generalizability is constrained by
the diversity of outcomes.
For AD, there is added complexity due to a lack of
consensus on standardized outcomes for longitudinal
observational studies, poor transferability of outcome
measures across studies and across medical and social
care systems, and a lack of relevant AD-related cog-
nitive and functional measures that are applicable
across the disease spectrum. How best to model the
natural history of AD using real-world data is also
unclear: disease modeling is particularly challeng-
ing because the association of changes in cognition,
function, and behavior with disease progression is
uncertain [6, 7].
Incorporating the assessment of AD-related out-
comes into real-world settings requires consensus
between stakeholders. RWE helps to inform regula-
tors (on treatment patterns, effectiveness, and risk);
payers, Health Technology Assessment (HTA) bod-
ies, and healthcare providers (HCPs; on economic
value/resource utilization, clinical effectiveness rel-
ative to current standard-of-care treatments, and
patient-relevant outcomes, including quality of life
[QoL]); industry (on product effectiveness and
safety, research and development, pricing, and
manufacturing); and scientists (on mechanisms
and diagnostic/treatment pathways) to accelerate
decision-making on new and existing treatments
[8–10].
Innovative Medicines Initiative (IMI) projects,
such as the European Medical Information Frame-
work (EMIF) [11] (http://www.emif.eu) and the
European Prevention of Alzheimer’s Dementia
(EPAD) project [12] (http://ep-ad.org/), partly
address the problems of combining different types of
data and identifying at-risk individuals before symp-
toms develop. However, no large-scale international
projects have provided a framework for mapping and
linking AD progression to QoL and resource utiliza-
tion across the RWE spectrum. This article overviews
the aims, objectives, methods, and deliverables of the
ROADMAP (Real world Outcomes across the AD
spectrum for better care: Multi-modal data Access
Platform) project, which was undertaken to address
these and other limitations. Findings of ROADMAP
are not presented here but will be published in the
future.
WHAT IS ROADMAP?
ROADMAP is a public-private advisory partner-
ship to evaluate the usability of multiple RWE
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data sources in the decision-making process for
developing new treatments in AD (http://roadmap-
alzheimer.org). This two-year research project was
recently completed and was funded through IMI2,
Europe’s largest public-private initiative to accelerate
new drug development. IMI2 partners the Euro-
pean Union’s (EU) Horizon 2020 program (https://ec.
europa.eu/programmes/horizon2020/) with the Euro-
pean pharmaceutical industry, represented by the
European Federation of Pharmaceutical Industries
and Associations (EFPIA; https://www.efpia.eu).
The IMI2 design facilitates collaboration between
regulatory bodies, payers, patient organizations,
pharmaceutical companies, academia, and other
important stakeholders. Indeed, the ROADMAP con-
sortium includes 26 partners: 12 European academic
institutions, nine pharmaceutical companies from
Europe and the USA, one regulatory body, one
HTA body, one patient organization, one technol-
ogy enterprise, and one research service company
(http://roadmap-alzheimer.org/partners/). This broad
stakeholder base is essential to establish a sustainable
consensus on how to apply RWE to optimally benefit
patients, and to better prepare healthcare, social care,
and data systems for emerging new treatments.
ROADMAP AIMS, OBJECTIVES,
METHODS, AND DELIVERABLES
Aims and objectives
ROADMAP aimed to evaluate the feasibility and
utility of an integrated data environment for RWE
in AD by evaluating disease progression and health
economic models. ROADMAP developed, tested,
and will advise on: consensus-based key disease and
patient outcome measures endorsed by stakeholder
groups for making informed funding and treatment
decisions; data integration tools for dataset charac-
terization and outcome classification, data sourcing,
data standards, and a software application reposi-
tory; guidelines on the handling and interpretation
of RWE data; and ideal specifications for disease
and cost-effectiveness models. In parallel, tools for
stakeholder engagement were developed, the usabil-
ity of RWE to demonstrate the economic value of new
AD treatments was evaluated, and the critical ethical,
legal, and social barriers to using RWE in AD were
mapped.
Table 1 summarizes the ROADMAP objectives,
administered through eight Work Packages (WPs).
Table 1
ROADMAP objectives
Project management and coordination
Establish a project management and governance structure to deliver the project to plan, and within time and budget; to ensure effective
communication between consortium members; and to develop a plan for phase 2 of the ROADMAP initiative (WP1)
Outcome deﬁnition
Define and catalog outcomes across the spectrum of AD, prioritize these from the perspective of the different stakeholders, and assess
the availability of data from real-world data sources on these outcomes (WP2)
Data integration
Identify and pool AD-related RWE data and establish solutions for how to combine different RWE sources with RCT data supporting
pharmacoeconomic evaluation (WP3)
Disease modeling and simulation
Develop and validate a core disease progression model combining diverse datasets, facilitating analysis of disease trajectories and the
effect of interventions on disease trajectories (WP4)
Economic modeling
Identify the specific data and analytical methods required to develop a robust state-of-the-art cost-effectiveness model capable of
evaluating AD interventions that meet the needs of regulators, payers, HTA agencies, service providers, caregivers, and industry
(WP5)
HTA and regulatory engagement
Develop guiding principles and recommendations from regulators/payers/HTA agencies for the development and incorporation of RWE
into clinical and market-access development plans for AD (WP6)
Patient and clinical engagement
Develop and implement a communication strategy focusing on the needs of patients and healthcare professionals (WP7)
Ethical, legal, and social implications
Map the critical ethical, legal, and social issues that arise from creating an RWE platform, reusing existing health data and pooling data
from different data sources (WP8)
AD, Alzheimer’s disease; HTA, health technology assessment; RCT, randomized controlled trial; RWE, real-world evidence; WP, Work
Package.
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Methods
ROADMAP explored the integration of evidence
from broad-based national population EHRs with in-
depth cohort data and tightly-focused RCT data. This
approach allowed the triangulation of complementary
evidence between data types, playing to the strengths
of each in addressing research questions. For exam-
ple, detailed etiologic inference from disease-specific
cohorts was related to actual population benefit in
EHRs. These data were used to generate and test dis-
ease progression and health economic models, and
to generate research questions intended to inform the
design of a new generation of cohorts and clinical
trials.
Diverse national databases and registries were
available to ROADMAP (Supplementary Table 1).
Data from approximately 200 million patients were
drawn from several EU Member States (notably Den-
mark, France, Netherlands, Spain, Sweden, UK) and
included 75 national databases and clinical registries,
>40 cohorts, several studies of patients using wear-
ables and smart devices, five dementia-relevant trials,
and four RCT placebo arms.
ROADMAP used established technologies that
facilitate rapid and secure data acquisition, access,
and analysis. These technologies were developed fur-
ther to test the feasibility of using methods primarily
developed for broader EHRs for the harmoniza-
tion of cohort and RCT data. Technologies and
methods developed in the IMI EMIF project [11]
were used for data source fingerprinting/cataloging
and for EHR data extraction and integration across
diverse sources and countries. The intention was to
map the current landscape of available data across
data sources, including EHRs, and to identify data
gaps, which should be closed to provide full cov-
erage of relevant outcomes. Cross-cohort analysis
was performed using the Dementias Platform UK
(DPUK; https://www.dementiasplatform.uk) and the
EMIF-AD project integrated informatics environ-
ment (https://emif-catalogue.eu). DPUK uses the UK
Secure e-Research Platform (UKSeRP) to provide
access to dementia-dedicated data, and enables the
analysis of cohort data alongside EHRs and other
national database records. EMIF-AD uses Jerboa
and TranSMART technologies to enable the analysis
of EHR data alongside cohort data. The integra-
tion of data and analyses was tested by applying
unified data extraction and integration technology
simultaneously across platforms and remote data
locations.
Fig. 1. The ROADMAP data cube: the different data sources
covered the whole disease spectrum and contained diverse out-
comes/variables.
Information was obtained on what constitutes
a meaningful delay in disease progression, from
clinical (including cognitive, functional, and behav-
ioral changes), humanistic (QoL), and economic
perspectives. A ‘data cube’ was used to identify
outcomes/variables available from the different data
sources and their relation to disease severity (Fig. 1).
In addition, ROADMAP identified existing relevant
disease models through literature review and contri-
butions from academic and industry partners. These
provided an initial framework of reference across
the disease spectrum, and were tested and validated
using outcomes and datasets also identified during
the project.
Specifications for a proof-of-concept cost-
effectiveness model to evaluate AD treatments
were also developed, and data gaps identified and
summarized for future research. These specifications
were evaluated considering wider manufacturing,
reimbursement, and health policy perspectives as
well as best practice within the economic modeling
community.
A regulatory and HTA expert advisory group was
established, comprising individuals with expertise
in regulatory, HTA, and payer requirements across
Europe. The objectives of this group were to pro-
vide feedback where needed, and to ensure that
ROADMAP outputs were of high scientific qual-
ity and applicable in a regulatory and HTA context.
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Table 2
ROADMAP key deliverablesa
Deﬁning a minimum set of measurable real-world AD outcomes.
This was met in WP2 by developing a matrix of prioritized outcomes according to stakeholder group and, in collaboration with WP3,
mapping them against the data available from DPUK cohorts and other relevant European datasets.
Developing recommendations on RWE-appropriate, AD-related cognitive, functional, and behavioral outcomes.
This was met by work conducted under WP2, WP3, and WP4 using cohorts and other data sources to identify intermediate (and
possibly theragnostic) markers that may be transferable to clinical practice.
Identifying data sources and outlining a data strategy for RWE outcomes.
This was met in WP3 by providing an overview of data sources available throughout Europe (not just within the ROADMAP
consortium), the tools available for identifying and combining these data, and opportunities and strategies for pooling data.
Developing new methods for collecting RWE to improve how new treatments can be valued in AD.
This was met in WP2, WP3, and WP5-8 through engagement with regulators, payers, HTA bodies, patients, caregivers, industry, and
researchers. The use of smart devices for self-report, social media, and direct objective assessment applications was of particular
interest.
Providing recommendations for disease progression modeling.
This was met in WP4 using both hypothesis-driven and machine-learning approaches. Both approaches were informed by a review of
current models of AD pathology, and by using available datasets for validation of selected models.
Developing the concept of an integrated core health economic model of healthcare use/costs and health outcomes in AD.
This was met in WP5 in collaboration with WPs 2-4 and 6. It was evidenced on quality of life, resource utilization, and costs associated
with AD, and previous AD economic modeling studies, and used systematic reviews to improve the evidence base of long-term AD
cost-effectiveness modeling.
Identifying guiding principles on the use of RWE in AD in the regulatory/HTA context.
Partners in WP6 collected and collated regulatory and HTA-related data to identify possible recommendations for the development and
incorporation of RWE into clinical and market-access development plans for AD.
Developing requirements for an ethical, legal, and social issues framework for RWE in AD.
Partners in WP8 developed a report on ethical, legal, and social issues arising from the combination of datasets from multiple countries
for disease, health economic, and treatment modeling for AD, including requirements set out in national ethical and legal frameworks
governing local ethics approval.
aSee Table 1 for Work Packages. AD, Alzheimer’s disease; DPUK, Dementias Platform UK; HTA, health technology assessment; RWE,
real-world evidence; WP, Work Package.
A separate ethics advisory board, including internal
and external experts, was established to provide input
on the data integration tools and methodology devel-
oped by ROADMAP.
Deliverables and interim results
The ROADMAP key deliverables are summarized
in (Table 2). Initial results have already been
delivered, including a list of RWE outcomes for
AD, an initial set of communication tools, and
an overview of potential European RWE data
sources (https://roadmap-alzheimer.org/downloads/
deliverables/). However, the aim of the present paper
is not to report findings; further results and publi-
cations will become available in 2019. A strategy
was developed [13] for disseminating the results
from ROADMAP to the different stakeholders, and
also for sharing findings with and from neighboring
initiatives, such as EMIF (http://www.emif.eu),
AETIONOMY (http://www.aetionomy.eu/), Get-
Real (http://imi-getreal.eu/), EPAD (http://ep-
ad.org/), AMYPAD (http://amypad.eu), and BD4BO
(http://bd4bo.eu). This strategy targeted previously
disparate audiences, including regulators, payers,
HTA bodies, policy-makers, patients, and industry,
with the aim of providing an environment in which
a broad-based consensus could be established on
prioritizing AD-related outcomes, data access and
integration protocols, and model development and
testing procedures. Key messages were tailored to
the interests of the target audiences, and the most
appropriate dissemination tools were identified and
developed to meet their needs. A second phase of
ROADMAP is planned, which will aim to address
the identified data gaps from the first phase of the
study and continue to engage with stakeholders
on methods for optimizing RWE capabilities for
activities required to demonstrate the value of new
treatments (WP1; Table 1).
THE LIKELY IMPACT OF ROADMAP
The ROADMAP deliverables are congruent with
the IMI2 aim of accelerating the development and
availability of new therapies (http://www.imi.europa.
eu/about-imi/mission-objectives). Networking of
multiple healthcare systems should increase com-
petitiveness by delivering knowledge more quickly
and cheaply than would otherwise be possible. The
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output of this collaboration is intended to provide
recommendations for: a minimum set of measurable
real-world patient outcomes; appropriate AD-related
cognitive, functional, and behavioral real-world out-
comes; disease progression and health economic
modeling; and optimal real-world data collection to
improve how new AD treatments can be valued.
ROADMAP provided an opportunity to overview the
numerous disease progression and economic mod-
els developed over the years by many researchers.
The immediate impacts from this project will likely
be largely instrumental, with patient health bene-
fits observed indirectly through more streamlined
decision-making to foster patient access to new ther-
apies. Understanding of the progression of AD across
the disease spectrum and measurement of treatment
benefits should also be improved.
LIMITATIONS AND CHALLENGES OF
ROADMAP
The main challenge of ROADMAP was to identify
and access suitable data in the short (2-year) project
time frame, which itself was a limitation. Creating a
3-dimensional overview across diverse data sources
from multiple countries, and deciding which of the
many possible AD-related outcomes were relevant,
were particularly challenging. The lack of consensus
on which standardized outcomes to use was a lim-
itation that still needs to be overcome. ROADMAP
therefore focused on integrating data sources acces-
sible through ROADMAP partners to provide proof
that technology solutions could be applied across the
various data sources.
CONCLUSIONS
ROADMAP was a collaborative foundation project
to identify, test, and evaluate the usability of multiple
RWE data sources in the decision-making process for
developing new treatments in AD. An unprecedented
depth and breadth of RWE data were used to gener-
ate and test disease progression and health economic
models, and to generate research questions intended
to inform the design of a new generation of cohorts
and clinical trials. The immediate impacts from the
project are likely to be largely instrumental, fostering
more streamlined decision-making to improve access
to new therapies, and providing a greater under-
standing of the progression of AD across the disease
spectrum.
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